Core Viewpoint - The newly issued "National Essential Drug Directory Management Measures" aims to update and optimize the essential drug list in response to the evolving needs of the healthcare sector and to ensure the availability of essential medications for citizens [3][5][8]. Summary by Sections Regulatory Framework - The updated measures incorporate legal policy foundations, including the "Basic Medical and Health Promotion Law" and the "Drug Administration Law," to enhance the management of essential drugs [5]. - The essential drug directory has been established since 1982, with several updates, the last being in 2018, which included 685 drugs [4][5]. Directory Structure Optimization - The new measures categorize essential drugs into chemical drugs, biological products, and traditional Chinese medicine, aligning with clinical pharmacological classifications [6]. - The emphasis is on including high-quality drugs that represent clinical mainstream treatments, rather than just low-cost options, to support tiered medical services [6][10]. Dynamic Adjustment Mechanism - The adjustment cycle for the essential drug directory is set to be no longer than three years, with provisions for timely updates as necessary [6]. - The measures stress the importance of clinical value and safety for drugs to be included in the directory, which is crucial for long-term business development [6][9]. Monitoring and Evaluation - A comprehensive evaluation system will be established to monitor the use of essential drugs, focusing on safety, effectiveness, economic viability, and innovation [7]. - The evaluation results will serve as a core evidence basis for future adjustments to the directory [7]. Industry Impact - The new measures are expected to accelerate industry transformation, pushing companies towards a clinical value-oriented approach [8][9]. - The inclusion of innovative drugs, particularly those with significant clinical efficacy and reasonable pricing, will create market opportunities for domestic pharmaceutical companies [9][10]. - The essential drug directory will increasingly focus on selecting high-value clinical drugs, marking a shift from merely ensuring supply to prioritizing clinical effectiveness [10].